Try our Advanced Search for more refined results

In Re: Nexium (Esomeprazole) Antitrust Litigation

Track this case

Case Number:

1:12-md-02409

Court:

Massachusetts

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

William G. Young

Firms

Companies

Sectors & Industries:

  1. March 07, 2014

    Judge Mulls Revival Of Nexium Pay-For-Delay Row

    A Massachusetts federal judge on Friday requested further briefing on whether he should reconsider portions of an order that granted victories to drugmakers Ranbaxy Inc. and Teva Pharmaceutical Industries Ltd. in a pay-for-delay class action involving the heartburn drug Nexium.

  2. March 03, 2014

    Nexium Buyers Urge Judge To Rethink Ranbaxy Win In MDL

    New evidence from the U.S. Food and Drug Administration shows that Ranbaxy Inc. could have received approval for a generic version of heartburn drug Nexium far sooner than it did, direct purchasers told a Massachusetts federal judge on Friday in a bid to revive their pay-for-delay suit against the drugmaker.

  3. January 14, 2014

    AstraZeneca Can't Duck Pharmacies' Claims In Nexium MDL

    AstraZeneca PLC couldn't convince a Massachusetts federal judge to shave several chain pharmacies' claims from multidistrict litigation alleging the company delayed the entry of generic Nexium, with the court on Monday rejecting AstraZeneca's argument that the retailers couldn't prove they suffered any injury.

  4. December 11, 2013

    Nexium Direct Purchasers Win Class Cert. In Antitrust MDL

    A Massachusetts judge granted class certification on Wednesday to a group of direct purchasers alleging AstraZeneca PLC and others breached antitrust laws by engineering the delay of a generic form of heartburn drug Nexium.

  5. November 27, 2013

    AstraZeneca, Ranbaxy Can't Ax Claims In Nexium Antitrust MDL

    A Massachusetts federal judge on Wednesday rejected AstraZeneca PLC and Ranbaxy Inc.'s bid to dismiss as time-barred certain claims in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca's heartburn drug Nexium.

  6. November 14, 2013

    Nexium Buyers Win Class Cert In AstraZeneca Antitrust MDL

    A Massachusetts federal judge certified a class of Nexium end-buyers on Thursday who accused AstraZeneca PLC and others of violating antitrust laws by delaying a generic version of AstraZeneca's heartburn drug, ruling the class met adequacy and predominance requirements.

  7. October 16, 2013

    Time Limit Dooms Nexium Antitrust Claims, AstraZeneca Says

    AstraZeneca PLC and Ranbaxy Inc. filed for partial summary judgment Tuesday in multidistrict litigation alleging the companies violated antitrust laws by agreeing to delay entry of a generic version of AstraZeneca's heartburn drug Nexium, saying a four-year statute of limitations on some claims has run out.

  8. September 17, 2013

    Dukes Prevents Class Cert. In Nexium MDL, AstraZeneca Says

    AstraZeneca PLC and several generic-drug makers facing multidistrict antitrust litigation alleging they unlawfully delayed the market entry of a generic form of Nexium told a Massachusetts federal judge Monday that a "sprawling class" of the drug's third-party purchasers should not be certified in light of the Supreme Court's Wal-Mart Stores Inc. v. Dukes decision.

  9. September 12, 2013

    AstraZeneca Can't Dodge Nexium Antitrust Claims

    A Massachusetts federal judge Wednesday largely kept intact multidistrict litigation brought by direct- and third-party purchasers that allege AstraZeneca PLC and several generic-drug makers violated antitrust laws by entering into agreements to delay entry of a generic version of AstraZeneca's heartburn drug Nexium.

  10. January 25, 2013

    Nexium MDL Judge Scolds Attys For Lead Counsel 'Squabble'

    The Massachusetts federal judge handling multidistrict litigation over whether AstraZeneca PLC illegally delayed generic versions of its heartburn drug Nexium scolded plaintiffs' attorneys Thursday, using strong words to criticize a fight over who gets to be lead counsel.